Clinical Trial

Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)

Name: Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC) — clinical trial record (NCT07162883)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

The primary purpose of this study is to demonstrate Pharmacokinetic similarity in exposure after the initial dose and at steady state of QL2107 compared with Keytruda.

Trial Details

NCT Number	NCT07162883
Lead Sponsor	Qilu Pharmaceutical Co., Ltd.
Conditions	Carcinoma, Non-Small-Cell Lung
Enrollment	122 participants
Start Date	2025-09-01
Primary Completion	2026-12-31 (estimated)
Study Completion	2027-05-31 (estimated)
Updated on ClinicalTrials.gov	2025-09-09